NCT04665076 2020-12-11
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
Hebei Senlang Biotechnology Inc., Ltd.
Chinese PLA General Hospital
Seoul National University Hospital
SPGO Research Mannheim GmbH
Cylene Pharmaceuticals